{"disease":{"id":"breast-cancer-non-small-lung-cancer","name":"breast cancer non small lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02728596","title":"S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3665,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03939481","title":"Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1336,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03401385","title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":890,"lead_sponsor_name":"Daiichi Sankyo Co., Ltd.","has_results":false},{"nct_id":"NCT07469709","title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","phase":"","overall_status":"RECRUITING","enrollment_count":850,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT04644068","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":702,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05123482","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT07169994","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":414,"lead_sponsor_name":"MediLink Therapeutics (Suzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07259226","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06272864","title":"BostonGene and Exigent Genomic INsight Study","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"BostonGene","has_results":false},{"nct_id":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Simcha IL-18, Inc.","has_results":false},{"nct_id":"NCT04258813","title":"Onco-primary Care Networking to Support TEAM-based Care","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"PMV Pharmaceuticals, Inc","has_results":false},{"nct_id":"NCT06500455","title":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":269,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03568656","title":"Study to Evaluate CCS1477 in Advanced Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"CellCentric Ltd.","has_results":false},{"nct_id":"NCT04332653","title":"NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"NeoImmuneTech","has_results":true},{"nct_id":"NCT06253520","title":"Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06695845","title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT05955105","title":"A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Innolake Biopharm","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05180474","title":"GEN1047 for Solid Tumors - First in Human (FIH) Trial","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":179,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT02308020","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03729596","title":"MGC018 With or Without MGA012 in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":143,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02391480","title":"A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03154190","title":"Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02952729","title":"Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06500481","title":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01660776","title":"BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT04504916","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT03392233","title":"Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT03149549","title":"PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":99,"lead_sponsor_name":"CytomX Therapeutics","has_results":true},{"nct_id":"NCT02223052","title":"Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT04244552","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Atreca, Inc.","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT01862081","title":"A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04916002","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT02897375","title":"Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05403554","title":"A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Light Chain Bioscience - Novimmune SA","has_results":false},{"nct_id":"NCT03775850","title":"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Evelo Biosciences, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}